Fig. 4: MAGL regulates the self-renewal and tumorigenesis of GSCs.

a Immunoblot (IB) analysis of MAGL in GSCs (578 cells) infected with a MAGL-expressing lentiviral or vector construct. α-tubulin was used as a loading control. b Limiting dilution assays (LDAs), performed in 578-vector and 578-MAGL cells. (n = 24, **P < 0.01, t-test). c IB analysis of MAGL in GSCs (0502 cells) infected with a MAGL-expressing lentiviral or vector construct. α-tubulin was used as a loading control. d LDAs, performed in 0502- vector and 0502-MAGL cells. (n = 24, **P < 0.01, t-test). e IB analysis of MAGL in GSCs (528 cells) infected with a shMAGL-expressing lentiviral or shCtrl construct. α-tubulin was used as a loading control. f LDAs, performed in 528-shCtrl, 528-shMAGL-1, and 528-shMAGL-3 cells. (n = 24, **P < 0.01, t-test). g IB analysis of MAGL in GSCs (X01 cells) infected with a shMAGL-expressing lentiviral or shCtrl construct. α-tubulin was used as a loading control. h LDAs, performed in X01-shCtrl, X01-shMAGL-1, and X01-shMAGL-3 cells. The well-formed sphere was counted at day 16. (n = 24, **P < 0.01, t-test). i IB analysis of ARS2 and MAGL in GSCs (X01 cells) infected with a shARS2- or MAGL-expressing lentiviral construct, both shARS2- and MAGL-expressing lentiviral constructs, or a shCtrl construct. j LDAs, performed in GSCs (X01 cells) infected with a shARS2- or MAGL-expressing lentiviral construct, both shARS2- and MAGL-expressing lentiviral constructs, or a control construct. The well-formed sphere was counted at day 7. (n = 24, *P < 0.05, **P < 0.01, t-test). k Kaplan–Meier survival analysis of mice implanted with X01 cells infected with shMAGL-expressing lentiviral or shCtrl construct (n = 7; 2 × 10⁴ cells injected per mouse, log-rank test). Median survival of the orthotopic mice injected with X01-shCtrl, X01-shMGLL-1, or X01-shMGLL-3 was 36 days, 42 days, and 49 days, respectively.